natgillin/translations-raw huggingface dataset:
Saxagliptin (n=183) provided significant improvements in HbA1c, FPG, and PPG compared to placebo (n=180).
Saksagliptin (n=183) je izboljšal HbA1c, glukozo v plazmi na tešče in postprandialno glukozo bistveno bolj kot placebo (n=180).
Saxagliptin (n=186) provided significant improvements in HbA1c, FPG, and PPG compared to placebo (n=175).
Izboljšanja HbA1c, postprandialne glukoze in glukoze v plazmi na tešče so se ohranila do
Saxagliptin (n=186) provided significant improvements in HbA1c, FPG, and PPG compared to placebo (n=175).
Saksagliptin (n=186) je izboljšal HbA1c, glukozo v plazmi na tešče in postprandialno glukozo bistveno bolj kot placebo (n=175).
Saxagliptin (n=250) provided significant improvements in HbA1c, FPG, and PPG compared to titration to a higher dose of glibenclamide (n=264).
Saksagliptin (n=250) je izboljšal HbA1c, glukozo v plazmi na tešče in postprandialno glukozo bistveno bolj kot titriranje do večjega odmerka glibenklamida (n=264).
Saxagliptin 5 mg
5 mg saksagliptina
Saxagliptin add-on combination therapy with insulin (with or without metformin)
Saksagliptin kot dodatek zdravljenju z insulinom (z ali brez metformina)
Saxagliptin add-on combination therapy with metformin and sulphonylurea
Dodatek saksagliptina kombiniranemu zdravljenju z metforminom in sulfonilsečnino
Saxagliptin add-on to glibenclamide therapy
Saksagliptin kot dodatek zdravljenju z glibenklamidom
Saxagliptin add-on to metformin therapy
Saksagliptin kot dodatek k zdravljenju z metforminom
Saxagliptin add-on to metformin therapy
Saksagliptin kot dodatek zdravljenju z metforminom
Saxagliptin add-on to thiazolidinedione therapy
Saksagliptin kot dodatek zdravljenju s tiazolidindionom
Saxagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
Zmanjšuje tudi količino glukoze, ki jo tvorijo jetra, in sicer tako, da zvišuje raven insulina in znižuje raven hormona glukagona.
Saxagliptin and metformin have a negligible influence on the ability to drive and use machines.
Saksagliptin in metformin imata zanemarljiv vpliv na sposobnost upravljanja vozil ali uporabo orodij ali strojev.
Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus - thrombolysis in myocardial infarction (SAVOR) study
Študija SAVOR: ocena žilnih izidov, zabeleženih pri bolnikih s sladkorno boleznijo ob saksagliptinu - tromboliza pri miokardnem infarktu
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction (SAVOR) Study
Preskušanje SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction - Ocena žilnih izidov, zabeleženih pri bolnikih s sladkorno boleznijo ob saksagliptinu - tromboza in miokardni infarkt)
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction (SAVOR) Study
Preskušanje SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction -Ocena žilnih izidov, zabeleženih pri bolnikih s sladkorno boleznijo ob saksagliptinu - tromboza in miokardni infarkt)
Saxagliptin in combination with a fixed, intermediate dose of a sulphonylurea (glibenclamide 7.5 mg) was compared to titration to a higher dose of glibenclamide (approximately 92% of patients in the placebo plus glibenclamide group were up-titrated to a final total daily dose of 15 mg).
Saksagliptin v kombinaciji s stalnim, srednje velikim odmerkom sulfonilsečnine (7,5 mg glibenklamida) so primerjali s povečevanjem odmerka glibenklamida (približno 92 % bolnikom v skupini s placebom in glibenklamidom so odmerek povečevali do končnega celotnega dnevnega odmerka 15 mg).
Saxagliptin in combination with metformin as initial therapy
Saksagliptin v kombinaciji z metforminom kot uvodno zdravljenje
Saxagliptin in combination with metformin for glycaemic control
Saksagliptin v kombinaciji z metforminom za urejenost glikemije
Saxagliptin is a dipeptidyl peptidase 4 (DPP4) inhibitor.
Saksagliptin je zaviralec dipeptidil peptidaze 4 (DPP-4).
Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor.
Saksagliptin je zelo močan (Ki: 1,3 nM), selektiven, reverzibilen in kompetitiven zaviralec DPP-4.
Saxagliptin is not recommended for use in patients with end-stage renal disease (ESRD) requiring haemodialysis.
Saksagliptin ni priporočljiv za uporabo pri bolnikih s končno odpovedjo ledvic, ki potrebujejo hemodializo.
Saxagliptin monotherapy
Saksagliptin
Saxagliptin or metformin has a negligible influence on the ability to drive and use machines.
Saksagliptin ali metformin imata zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Saxagliptin significantly decreased HbA1c compared with placebo; the HbA1c change for saxagliptin was -0.9% at Week 12 (HbA1c change of -0.4% for placebo).
Saksagliptin je v primerjavi s placebom značilno znižal HbA1c: sprememba HbA1c s saksagliptinom je bila 12. teden –0,9 % (s placebom –0,4 %).
Saxagliptin twice daily add-on to metformin therapy
Saksagliptin dvakrat na dan kot dodatek k zdravljenju z metforminom
Saxagliptin with a thia- zolidinedione
Saksagliptin s
Saxagliptin with metformin1
Saksagliptin z
Saxagliptin/dapagliflozin combination: The reported adverse events of vulvovaginitis, balanitis and related genital infections from pooled safety analysis were reflective of the safety profile of dapagliflozin.
Kombinacija saksagliptina/dapagliflozina: Poročani neželeni učinki vulvovaginitis, balanitis in sorodne okužbe spolovil v kumulativni analizi varnosti odražajo varnostne značilnosti dapagliflozina.
Saxagliptin: Concomitant administration of saxagliptin with the moderate inhibitor of CYP3A4/5 diltiazem, increased the Cmax and AUC of saxagliptin by 63 % and 2.1-fold, respectively, and the corresponding values for the active metabolite were decreased by 44 % and 34 %, respectively.
Saksagliptin: Sočasna uporaba saksagliptina z zmernim zaviralcem CYP3A4/5 diltiazemom je zvišala Cmax saksagliptina za 63 % in njegovo AUC za 2,1-krat ter znižala Cmax aktivnega presnovka za 44 % in njegovo AUC za 34 %.
Saxagliptin: Elderly patients (65–80 years) had about 60 % higher saxagliptin AUC than young patients (18–40 years).
Saksagliptin: Starejši bolniki (65-80 let) so imeli AUC saksagliptina približno 60 % višjo kot mladi bolniki (18-40 let).
Saxagliptin: In subjects with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment the exposures to saxagliptin were 1.1-, 1.4- and 1.8-fold higher, respectively, and the exposures to BMS-510849 (saxagliptin metabolite) were 22 %, 7 %, and 33 % lower, respectively, than those observed in healthy subjects.
Saksagliptin: V primerjavi z zdravimi osebami je bila pri bolnikih z blago okvaro jeter (Child-Pugh razred A) izpostavljenost saksagliptinu 1,1-krat večja in izpostavljenost BMS-510849 (presnovek saksagliptina) 22 % manjša, z zmerno okvaro jeter (Child-Pugh razred B) 1,4-krat večja oziroma 7 % manjša ter s hudo okvaro jeter (Child-Pugh razred C) 1,8-krat večja oziroma 33 % manjša.
Saxagliptin: The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5).
Saksagliptin: Presnova saksagliptina poteka predvsem s citokromom P450 3A4/5 (CYP3A4/5).
Saxenda is a medicine used along with diet and exercise to help manage weight in adults:
Saxenda je zdravilo, ki se uporablja skupaj z dieto in telesno vadbo za obvladovanje telesne mase pri odraslih: ki so debeli (imajo indeks telesne mase oz.
SBP (mmHg)2
Vrednost SBP (mmHg)2
SBP (mmHg)2
Vrednost SBP (mmHg)2, 3
SBP (mmHg)2, 3
Vrednost SBP (mmHg)2
SBP (mmHg)2, 3
Vrednost SBP (mmHg)2, 3
SBP (mmHg)3
Vrednost SBP (mmHg)3
SBP (mmHg)3
Vrednost ŞBP (mmHg)3
SBS patients are to be kept under close surveillance according to clinical treatment guidelines.
Bolnike s SKČ je treba skrbno spremljati v skladu s smernicami kliničnega zdravljenja.
SC
50
SC (cattle) IM (pigs)
s.c. (govedo), i.m. (prašiči)
SC (cattle), IM (pigs)
s.c. (govedo), i.m. (prašiči)
SC for Chronic Lymphocytic Leukaemia
s.c. pri kronični limfocitni levkemiji
SC for Non-Hodgkin’s Lymphoma
s.c. pri ne-Hodgkinovem limfomu
SC formulation in administration system
Subkutana oblika v aplikacijskem sistemu
SC or in ovo route
Subkutana in in ovo uporaba
SC or IV injection.
s.c. ali i.v.
SC or IV injection.
s.c. ali i.v. injekcija
SC or IV use only.
Samo za s.c. ali i.v. uporabo.
SC use only
Samo za s. c. uporabo.
SC-I was a non-inferiority study that compared the efficacy and safety of tocilizumab 162 mg administered every week versus 8 mg/kg intravenous in 1262 patients with RA.
SC-I je bila študija ne-inferiornosti, ki je pri 1262 bolnikih z revmatoidnim artritisom primerjala učinkovitost in varnost 162 mg tocilizumaba, apliciranega vsak teden z 8 mg/kg tocilizumaba intravensko.
Scab
krasta
Scabs
kraste
Scales and crusts are then carefully removed and all lesion surfaces are gently roughened.
Nato previdno odstranite luske in kraste in površine vseh lezij nežno podrgnite, da postanejo hrapave.
Scalp
Lasišče
Scaly, flaky, itchy and red skin
luskasta, srbeča in rdeča koža
Scaly, peeling skin
luščenje kože,
SCAN THIS CODE TO LAUNCH
SKENIRAJTE TO KODO ZA ZAGON
Scan with moderate beta-amyloid deposition
Rezultat preiskave z zmernim ß-amiloidnim odlaganjem
Scan with pronounced beta-amyloid deposition
Rezultat preiskave z izrazitim ß-amiloidnim odlaganjem
Scan without beta-amyloid deposition
Rezultat preiskave brez ß-amiloidnega odlaganja
Scar
brazgotina
Scarf: for head and neck.
Šal: za glavo in vrat.
Scarring
Brazgotinj enje
Scarring in the kidney that may reduce kidney function
brazgotinjenje ledvic, ki lahko zmanjša delovanje ledvic,
Scarring may also occur in affected areas.
Na prizadetih področji se lahko pojavijo tudi brazgotine.
Scarring of the conjunctiva (the protective layer over the white of your eye) with damage where it joins to the inside of the eyelids (fornix shortening)
brazgotine veznice (zaščitne plasti, ki prekriva beli del očesa) s poškodbo predela, kjer veznica prehaja v notranjost očesnih vek (skrajšanje forniksa)
Scars
imeti modric,
Scattered body pain, including in muscles and joints, back pain Fluid retention, altered medicine levels.
bolečine, razpršene po vsem telesu, vključno z mišicami in sklepi, bolečine v hrbtu zastajanje tekočine v telesu, spremenjene koncentracije zdravil v krvi
SCC in MGIT® n/N (%)
SCC pri MGIT® n/N (%)
SCC in the treatment area was reported in no patients (0 of 184 patients previously treated with ingenol mebutate gel) in the three prospective, observational long term 1 year follow-up studies.
V treh prospektivnih, opazovalnih dolgotrajnih študijah z 1-letnim spremljanjem niso pri nobenem od bolnikov opazili skvamoznega karcinoma (0 od 184 bolnikov, predhodno zdravljenih z gelom z ingenol mebutatom).
SCC of the skin (d), seborrheic keratosis, skin papilloma
ploščatocelični karcinom kože(d), seboroična keratoza, kožni papilom
SCC on solid media n/N (%)
SCC na trdem gojišču n/N (%)
Scedosporium spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with S. apiospermum and in 2 (both partial responses) of 7 patients with S. prolificans infection.
Scedosporium spp.: Uspešen odziv na zdravljenje z vorikonazolom so ugotovili pri 16 (6 popolnih, 10 delnih odzivov) od 28 bolnikov, okuženih s S. apiospermum, in pri 2 (oba delna odziva) od 7 bolnikov, okuženih s
Scedosporium spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with S. apiospermum and in 2 (both partial responses) of 7 patients with S. prolificans infection.
Scedosporium spp.: Uspešen odziv na zdravljenje z vorikonazolom so ugotovili pri 16 (6 popolnih, 10 delnih odzivov) od 28 bolnikov, okuženih s S. apiospermum, in pri 2 (oba delna odziva) od 7 bolnikov, okuženih s S. prolificans.
SCENESSE 16 mg implant afamelanotide Subcutaneous use
SCENESSE 16 mg implantat afamelanotid subkutana uporaba
Scenesse has been authorised under ‘exceptional circumstances’.
Zdravilo Scenesse je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
SCENESSE is a medicine that contains the active substance afamelanotide.
SCENESSE je zdravilo, ki vsebuje zdravilno učinkovino afamelanotid.
SCENESSE is administered subcutaneously under aseptic conditions as described below.
Zdravilo SCENESSE se daje subkutano v aseptičnih pogojih, kot je opisano spodaj.
SCENESSE is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Zdravilo SCENESSE je indicirano za preprečevanje fototoksičnosti pri odraslih bolnikih z eritropoetsko protoporfirijo (EPP).
SCENESSE should be avoided during breastfeeding.
Uporabi zdravila SCENESSE med dojenjem se je treba izogibati.
SCENESSE should not be used during pregnancy.
Zdravilo SCENESSE se ne sme uporabljati med nosečnostjo.
SCENESSE should only be prescribed by specialist physicians in recognised porphyria centres and administration should be performed by a physician trained and accredited by the marketing authorisation holder to administer the implant.
Zdravilo SCENESSE smejo predpisati samo specialisti v priznanih centrih za porfirijo, uporabljajo pa ga lahko samo zdravniki, ki jih je imetnik dovoljenja za promet z zdravilom usposobil in pooblastil za uporabo implantata.
Schedule
Shema
Schedule
Shema cepljenja
Schedule
Shema zdravljenja
Schedule should be adjusted accordingly (see section “dosage”). .
Razpored cepljenja je zato potrebno ustrezno prilagoditi (glejte poglavje »Odmerjanje«).
Schematic diagram of the pen
Shematični prikaz injekcijskega peresnika
Schering-Plough S.A., 2, rue Louis Pasteur; 14200 Hérouville St Clair, France
Schering-Plough S.A., 2, rue Louis Pasteur; 14200 Hérouville St Clair, Francija
Schizophrenia in adolescents with oral aripiprazole
Uporaba peroralnega aripiprazola pri shizofreniji pri mladostnikih
Schizophrenia Studies: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point - LOCF for Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set
Študije shizofrenije: lestvica pozitivnih in negativnih simptomov pri shizofreniji (Positive and Negative Syndrome Scale for Schizophrenia-PANSS) Skupna ocena – sprememba od začetne vrednosti do končnega rezultata LOCF za študije R076477-SCH-303, R076477-SCH-304 in R076477-SCH-305: analizirana skupina, ki so jo nameravali zdraviti.
Schizophrenia Studies: Proportion of Subjects with Responder Status at LOCF End Point
Študije shizofrenije: Delež preiskovancev, ki so se odzvali na zdravljenje ob koncu LOCF
Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn.
in se uporablja za zdravljenje naslednjih bolezni: shizofrenije, bolezni s simptomi, kot so prisluhi, prividi ali občutki, ki niso povezani z realnostjo, zmotna prepričanja, nenavadna sumničavost in postopno izogibanje socialnim stikom.
Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn.
uporablja za zdravljenje naslednjih bolezni: shizofrenije, bolezni s simptomi, kot so prisluhi, prividi ali občutki, ki niso povezani z realnostjo, zmotna prepričanja, nenavadna sumničavost in postopno izogibanje socialnim stikom.
schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
shizofrenijo, tj. duševno boleznijo s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi ali sliši stvari, ki jih ni), sumničavost ter blodnje (zmotna prepričanja).
schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
shizofrenijo, tj. duševno boleznijo s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi in sliši stvari, ki jih ni), sumničavost ter blodnje (zmotna prepričanja).
Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overall- lower incidence (25.8 %) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %).
Shizofrenija: v dolgoročnem 52-tedenskem nadzorovanem preskušanju je bila celotna incidenca EPS (vključno s parkinsonizmom, akatizijo, distonijo in diskinezijo) manjša (25,8 %) pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali haloperidol (57,3 %).
Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overall- lower incidence (25.8%) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3%).
Shizofrenija: v dolgoročnem 52-tedenskem nadzorovanem preskušanju je bila celotna incidenca EPS (vključno s parkinsonizmom, akatizijo, distonijo in diskinezijo) manjša (25,8 %) pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali haloperidol (57,3 %).
Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8%) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3%).
Shizofrenija: v dolgoročnem 52-tedenskem nadzorovanem preskušanju je bila celotna incidenca EPS (vključno s parkinsonizmom, akatizijo, distonijo in diskinezijo) manjša (25,8 %) pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali haloperidol (57,3 %).
Schizophrenia: the recommended starting dose for ABILIFY is 10 or 15 mg/day (i.e.
Shizofrenija: priporočeni začetni odmerek zdravila ABILIFY je 10 ali 15 mg/dan (tj.
Schizophrenia: the recommended starting dose for ABILIFY is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Shizofrenija: priporočeni začetni odmerek zdravila ABILIFY je 10 ali 15 mg/dan, vzdrževalni odmerek pa 15 mg/dan, uporabljen enkrat na dan ne glede na obroke.
Sciatica
išias
Sciatica,
zakasnitvij
Scientific conclusions
Znanstveni sklepi
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN RAZLOGI ZA SPREMEMBO POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Znanstveni zaključki in podlaga za spremembo pogojev dovoljenja za promet z zdravilom
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Znanstveni zaključki in podlaga za spremembo pogojev dovoljenj za promet z zdravilom
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATIONS
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR VARIATION TO THE TERMS OF THE MARKETING AUTHORISATIONS
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR VARIATION TO THE TERMS OF THE MARKETING AUTHORISATIONS
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR VARIATION TO THE TERMS OF THE MARKETING AUTHORISATIONS
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI SKLEPI IN PODLAGA ZA PRIPOROČILO ZA SPREMEMBO POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA PRIPOROČILO SPREMEMBE POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA, KI PRIPOROČA SPREMEMBO POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN UTEMELJITEV PRIPOROČILA ZA SPREMEMBO POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation
Znanstveni zaključki in podlaga za priporočilo za spremembo pogojev dovoljenja za promet z zdravilom
Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation
Znanstveni zaključki in podlaga za spremembo pogojev dovoljenja za promet z zdravilom
Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation
Znanstveni zaključki in podlage, ki priporočajo spremembo pogojev za pridobitev dovoljenja za promet
SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATIONS
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA PRIPOROČENO SPREMEMBO POGOJEV DOVOLJENJ ZA PROMET Z ZDRAVILOM
SCIENTIFIC CONCLUSIONS AND THE GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA PRIPOROČILO SPREMEMBE POGOJEV DOVOLJENJA ZA PROMET Z ZDRAVILOM
Scientific conclusions and the grounds recommending the variation to the terms of the Marketing Authorisation
Znanstveni zaključki in utemeljitev priporočila za spremembo pogojev dovoljenja za promet z zdravilom
Scientific literature indicates an interaction of tissue-type plasminogen activator (tPA) and C1INH containing medicinal products.
Znanstvena literatura navaja medsebojno delovanje zdravil, ki vsebujejo tkivni aktivator plazminogena (tPA) in zdravil, ki vsebujejo C1INH.
Scintimun 1 mg kit for radiopharmaceutical preparation
Scintimun 1 mg komplet za pripravo radiofarmaka
Scintimun 1 mg kit for radiopharmaceutical preparation besilesomab
SCINTIMUN 1 mg komplet za pripravo radiofarmaka besilesomab
Scintimun contains less than 1 mmol of sodium (23 mg) per vial, i.e. essentially ‘sodium- free’.
Zdravilo Scintimun vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni “brez natrija”.
Scintimun has no or negligible influence on the ability to drive and use machines.
Zdravilo Scintimun nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Scintimun is a kit for radioactive preparation.
Zdravilo Scintimun je komplet za pripravo radiofarmaka.
Scintimun is a sterile powder containing 1 mg of besilesomab per vial Scintimun.
Zdravilo Scintimun je sterilen prašek, ki v vsaki viali vsebuje 1 mg besilesomaba.
Scintimun is administered intravenously.
Zdravilo Scintimun se daje intravensko.
Scintimun is used for the preparation of a radioactive solution for injection of technetium(99mTc)- besilesomab.
Zdravilo Scintimun se uporablja za pripravo radioaktivne raztopine za injiciranje, ki vsebuje tehnecijev (99mTc) besilesomab.
Scintimun should be given to sufficiently hydrated patients.
Zdravilo Scintimun dajemo zadostno hidriranim preiskovancem.